Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study. 1988

A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland.

On the basis of observation that acyclovir potentiates the in-vitro antiviral activity of 3-azido-2',3'-dideoxythymidine (also known as azidothymidine or zidovudine) against human immunodeficiency virus (HIV), we administered a regimen of azidothymidine and acyclovir to eight patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. An oral regimen of 100 mg of azidothymidine and 800 mg of acyclovir every 4 hours was in general well tolerated, with the principal toxicity being megaloblastic erythroid changes. The pharmacokinetics of the two drugs were independent of each other. Six patients received the drug combination for at least 10 weeks; all had increased numbers of T4+ lymphocytes (P = 0.028), and two of three assessable patients had reversal of anergy. Two patients tested positive for serum HIV p24 antigen at entry, but became negative with treatment. Data for this small group suggest that this drug combination can be tolerated in patients with severe HIV infections; this study can be used as a basis for larger studies of this drug combination.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009422 Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle. Neurologic Disorders,Nervous System Disorders,Neurological Disorders,Disease, Nervous System,Diseases, Nervous System,Disorder, Nervous System,Disorder, Neurologic,Disorder, Neurological,Disorders, Nervous System,Disorders, Neurologic,Disorders, Neurological,Nervous System Disease,Nervous System Disorder,Neurologic Disorder,Neurological Disorder
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006377 T-Lymphocytes, Helper-Inducer Subpopulation of CD4+ lymphocytes that cooperate with other lymphocytes (either T or B) to initiate a variety of immune functions. For example, helper-inducer T-cells cooperate with B-cells to produce antibodies to thymus-dependent antigens and with other subpopulations of T-cells to initiate a variety of cell-mediated immune functions. Helper Cell,Helper Cells,Helper T Cell,Helper-Inducer T-Lymphocytes,Inducer Cell,Inducer Cells,T-Cells, Helper-Inducer,T-Lymphocytes, Helper,T-Lymphocytes, Inducer,Helper T-Cells,Cell, Helper T,Cells, Helper T,Helper Inducer T Lymphocytes,Helper T Cells,Helper T-Cell,Helper T-Lymphocyte,Helper T-Lymphocytes,Helper-Inducer T-Cell,Helper-Inducer T-Cells,Helper-Inducer T-Lymphocyte,Inducer T-Lymphocyte,Inducer T-Lymphocytes,T Cell, Helper,T Cells, Helper,T Cells, Helper Inducer,T Lymphocytes, Helper,T Lymphocytes, Helper Inducer,T Lymphocytes, Inducer,T-Cell, Helper,T-Cell, Helper-Inducer,T-Cells, Helper,T-Lymphocyte, Helper,T-Lymphocyte, Helper-Inducer,T-Lymphocyte, Inducer
D006402 Hematologic Diseases Disorders of the blood and blood forming tissues. Blood Diseases,Hematological Diseases,Blood Disease,Disease, Blood,Disease, Hematologic,Disease, Hematological,Diseases, Blood,Diseases, Hematologic,Diseases, Hematological,Hematologic Disease,Hematological Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency

Related Publications

A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
May 1990, The American journal of medicine,
A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
September 1989, The New England journal of medicine,
A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
January 1988, Annals of neurology,
A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
December 1999, Molecular pharmacology,
A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
May 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
January 2006, Antiviral therapy,
A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
May 1990, The American journal of medicine,
A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
September 1986, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
May 1990, The New England journal of medicine,
A Surbone, and R Yarchoan, and N McAtee, and M R Blum, and M Maha, and J P Allain, and R V Thomas, and H Mitsuya, and S N Lehrman, and M Leuther
January 1988, Annals of neurology,
Copied contents to your clipboard!